(English) Skolkovo and AstraZeneca launch medtech start-up acceleration

17 мая 2019

(English) Russia’s Skolkovo Foundation and AstraZeneca, a global biopharmaceutical company, are putting together a new joint acceleration program for projects that develop solutions for cancer therapy, cardiovascular diseases, metabolism and kidney problems, and respiratory diseases, Firrma.ru reported.

Primer Capital, a Russian venture fund with international presence, is acting as partner for the acceleration initiative.

The program will be aimed at identifying promising ideas and solutions to benefit the above-mentioned medical fields and also at addressing a range of specific problems in the existing healthcare system. Developing and promoting digital medicine solutions is also a goal for this year’s acceleration program.

Новости по теме
ИТ-компании попросили считать их в числе наиболее пострадавших от кризиса
База кейсов цифровой трансформации пополнилась 32 новыми цифровыми решениями
Минкомсвязь ограничила "бесплатный интернет" сайтами на российском ПО